COST-EFFECTIVENESS ANALYSIS OF TREATMENT WITH ABOBOTULINUMTOXINA COMPARED TO BEST SUPPORTIVE CARE IN PATIENTS WITH UPPER LIMB SPASTICITY IN SWEDEN

被引：0
|
作者：
Forsmark, A. [1 ]
Danchenko, N. [2 ]
Ertzgaard, P. [3 ]
Lundkvist, J. [4 ]
Rosengren, L. [5 ]
机构：
[1] Nord Hlth Econ, Gothenburg, Sweden
[2] Ipsen Pharma, Boulogne, France
[3] Linkoping Univ, Fac Hlth Sci, Linkoping, Sweden
[4] Ipsen Pharma, Uppsala, Sweden
[5] Ipsen Pharma, Kista, Sweden
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.2024
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND58
引用
收藏
页码：S338 / S339
页数：3
相关论文
共 50 条
  • [21] ECONOMIC BENEFITS OF ADULT UPPER LIMB SPASTICITY TREATMENT WITH ABOBOTULINUMTOXINA COMPARED WITH ONABOTULINUMTOXINA OR INCOBOTULINUMTOXINA: ANALYSIS OF A REAL-LIFE SETTING IN FRANCE
    Schnitzler, Alexis
    Rousset, Laure
    de Oliveira, Laurence
    Velickovic, Diana
    Danchenko, Natalya
    TOXICON, 2018, 156 : S103 - S104
  • [22] COST-EFFECTIVENESS OF SUNITINIB plus BEST SUPPORTIVE CARE FOR THE TREATMENT OF UNRESECTABLE PANCREATIC NEUROENDOCRINE TUMORS IN MEXICO
    Chi-Chan, A.
    Gutierrez-Colin, C., I
    Peniche-Otero, G.
    Herrera-Rojas, J.
    Mucino, E.
    Galindo-Suarez, R. M.
    VALUE IN HEALTH, 2012, 15 (04) : A218 - A218
  • [23] The cost-effectiveness of supportive periodontal care for patients with chronic periodontitis
    Gaunt, Francesca
    Devine, Maria
    Pennington, Mark
    Vernazza, Chris
    Gwynnett, Erika
    Steen, Nick
    Heasman, Peter
    JOURNAL OF CLINICAL PERIODONTOLOGY, 2008, 35 : 67 - 82
  • [24] Correction to: Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US
    Hardik Goswami
    Adnan Alsumali
    Yiling Jiang
    Matthias Schindler
    Elizabeth R. Duke
    Joshua Cohen
    Andrew Briggs
    Amy Puenpatom
    PharmacoEconomics, 2023, 41 : 605 - 605
  • [25] Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden
    Davidson, Thomas
    Husberg, Magnus
    Janzon, Magnus
    Oldgren, Jonas
    Levin, Lars-Ake
    EUROPEAN HEART JOURNAL, 2013, 34 (03) : 177 - 183
  • [26] Cost-effectiveness of sorafenib versus best supportive care in advanced hepatocellular carcinoma in Egypt
    Elsisi, Gihan Hamdy
    Nada, Yousery
    Rashad, Noha
    Carapinha, Joao
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (02) : 163 - 168
  • [27] A COST-EFFECTIVENESS ANALYSIS OF ONABOTULINUMTOXINA VERSUS BEST SUPPORTIVE CARE (BSC) FOR THE TREATMENT OF ANTICHOLINERGIC TREATMENT-REFRACTORY NEUROGENIC DETRUSOR OVERACTIVITY (NDO)
    Hamid, R.
    Loveman, C.
    Millen, J.
    Colayco, D.
    Stanisic, S.
    Gultyaev, D.
    VALUE IN HEALTH, 2014, 17 (07) : A470 - A470
  • [28] Cost-effectiveness of sorafenib compared to best supportive care in second line renal cell cancer from a payer perspective in Cyprus
    Petrou, Panagiotis
    Talias, Michael A.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (01) : 131 - 138
  • [29] Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment
    Starling, N.
    Tilden, D.
    White, J.
    Cunningham, D.
    BRITISH JOURNAL OF CANCER, 2007, 96 (02) : 206 - 212
  • [30] Cost-effectiveness of onabotulinumtoxinA for the treatment of wrist and hand disability due to upper-limb post-stroke spasticity in Scotland
    Doan, Q. V.
    Gillard, P.
    Brashear, A.
    Halperin, M.
    Hayward, E.
    Varon, S.
    Lu, Z. J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2013, 20 (05) : 773 - 780
12345